SCHEMBL4833288

SCHEMBL4833288

COc1cc2c(cc1OC)C(CCN1CCC(O)(c3ccc(Cl)cc3)CC1)N(C1(C=O)CCCCCC1)CC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.47
MAOA P21397 1/20 0.47
PTGS2 P35354 1/20 0.47
OPRK1 P41145 1/20 0.47
SLC6A3 Q01959 1/20 0.47
DRD2 P14416 5/20 0.45
DRD1 P21728 4/20 0.45
GRIN2C Q14957 5/20 0.43
GRIN2D O15399 4/20 0.43
GRIN3B O60391 4/20 0.43
GRIN1 Q05586 4/20 0.43
GRIN2A Q12879 4/20 0.43
GRIN2B Q13224 4/20 0.43
GRIN3A Q8TCU5 4/20 0.43
KCNH2 Q12809 1/20 0.43
MAPK1 P28482 2/20 0.42
TP53 P04637 1/20 0.42
TSHR P16473 1/20 0.42
KDM4E B2RXH2 1/20 0.41
CCR1 P32246 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833277 0.81 MTNR1B (0.61) NR1I2MAOAPTGS2OPRK1SLC6A3
SCHEMBL4838194 0.70 MTNR1B (0.53) OPRK1SLC6A3DRD2DRD1MAPK1
SCHEMBL4836853 0.70 DRD2 (0.41) DRD2KCNH2DRD3
SCHEMBL4839168 0.69 DRD2 (0.42) DRD2KCNH2DRD3
SCHEMBL4839599 0.68 OPRM1 (0.48) OPRK1SLC6A3DRD2DRD1OPRM1
SCHEMBL4832883 0.68 OPRM1 (0.48) OPRK1SLC6A3DRD2DRD1OPRM1
SCHEMBL11738985 0.66 ACHE (0.49) DRD2DRD1MAPK1KDM4EOPRM1
Methopholine SCHEMBL26169 0.65 NR1I2 (1.00) NR1I2MAOAPTGS2OPRK1SLC6A3
Methopholine SCHEMBL30492235 0.65 NR1I2 (1.00) NR1I2MAOAPTGS2OPRK1SLC6A3
SCHEMBL9844123 0.64 SIGMAR1 (0.65) MAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US claimed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US claimed
US-7384957-B2 3,4-dihydro-1H-isoquinolin-2-yl-derivatives H. LUNDBECK A/S (DK) 2008-06-10 US disclosed
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives H. LUNDBECK A/S (DK) 2005-03-31 US disclosed
EP-1458714-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. Lundbeck A/S (DK) 2004-09-22 EP disclosed
WO-2003051869-A1 3,4-DIHYDRO-1H-ISOQUINOLOIN-2-YL-DERIVATIVES H. LUNDBECK A/S (DK) 2003-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070713-A1 3 4-Dihydro-1h-isoquinoloin-2-yl-derivatives KCNJ2, KCNK2, KCNJ11 NR1I2 687/4885MAOA 2768/4885PTGS2 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.